A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX)

Trial Profile

A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX)

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs AZD 4547 (Primary) ; Capecitabine; Cisplatin
  • Indications Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FACING
  • Most Recent Events

    • 24 Nov 2015 Status changed from completed to discontinued as reported by ISRCTN: Current Controlled Trials Record.
    • 05 Mar 2015 Status changed from recruiting to completed, as reported by United Kingdom Clinical Research Network record.
    • 18 Jul 2014 Accrual to date is 20% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top